Pharmaceuticals

The The Indian Indian Pharmaceutical Pharmaceutical Association Association
PHARMA PROFESSIONAL
Vol. 64 July 2011
With the growth rate of 14 percent per year, the Indian pharmaceutical industry Inside Issue is well established for the rapid expansion. Indian Pharmaceutical Industry has made phenomenal progress over the years and made its impact in the global market. It has been recognized a reliable source in for drugs and drug intermediates and In Focus: Innovatives and Recent as Trends of CT Scanner Market pharmaceutical formulations. With the strengthening of the IPR scenario in the News Brief country, the quarter ended December 31, 2005 witnessed major changes in the Product Indian Focus pharmaceutical Exelon industry like the foreign MNCs increasing their presence in Stock Scan India through expansions and collaborations; Indian companies competing with them through new product launches and gaining more number of regulatory Upcoming Events approvals. Many multinational companies have penetrated into India with an objective to marketing drugs and conducting clinical trials. Thus, Indian pharmaceutical research, manufacturing and outsourcing have received an impetus, thereby creating an image of a potential Pharma market and land of opportunities in the pharmaceutical division. Moreover the new Draft Drug Policy 2006 was released during this quarter.
In In Focus: Focus: Innovatives Innovatives and and Recent Recent Trends Trends of of CT CT Scanner Scanner in in Market Market
Introduction A CT scan stands for Computed Tomography scan. It is also known as a CAT (Computer Axial Tomography) scan. It is a medical imaging method that employs tomography. Tomography is the process of generating a twodimensional image of a slice or section through a 3dimensional object (a tomogram). The medical device (the machine) is called a CTG scanner; it is a large machine and uses X-rays. It used to be called as an EMI scan, because it was developed by the company EMI. The CT scanner uses digital geometry processing to generate a 3dimensional (3-D) image of the inside of an object. Uses CT scanner can be used to produce images of: Thorax - The equipment can be used to demonstrate pulmonary lesions, kediastinal masses, rib metastasis and lymph node metastasis. Abdomen and pelvis - It can be used to demonstrate liver
9500
Future growth of ct Scanners
8500 Rs bn 7500
A joint Initiative by IPA and Cygnus 6500 to enable Pharma Professionals to be more successful 2011
Indian Pharmaceutical Association Kalina, Santacruz (E), Mumbai 400 098. Tel: 91-22-26671072; Fax: 91-22-26670744, Email:ipacentre@ipapharma.org:: www.ipapharma.org
1
2015*
Cygnus Business Consulting & Research Pvt. Ltd. Sources: Market Resources; Cygnus;*Indicates Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, Behind Image Hospital, Ameerpet, Hyderabad- 500 073. Estimated results Tel: +91-40-23430203-05, Fax: +91-40-23430201, Email: info@cygnusindia.com; Website: www.cygnusindia.com
Pharma Professional
July 2011
tumours, pancreatic tumours, adrenal tumours, enlarged intra abdominal lymph nodes. Musculoskeletal system - It can be used to demonstrate the bone architecture, spinal fractures, extent of muscle tumours, and extent of soft tissue masses. Radiotherapy - It can be used to plan the radiotherapy field, to assess response to radiotherapy in follow-up cases, to demonstrate the recurrence of the malignant disease. Market Size The market size of CT scanners in India was Rs5748.52m in 2010-11, a growth of 20% over the previous year. The high-end CT scanner segment accounted for approximately 55% of the total market. Of this, Cardiac high-end segment accounted for a major share that is 40%, amounting to Rs1315m in values. The Non-Cardiac and Radiological high-end segment is valued at Rs485.26m and 15% share. The Value segment has shown appreciable growth and accounted for 30% share of the total market, valued at Rs1130m. The Entry Level segment held 10% of the market and valued at Rs5748.52m. There is a major shift in demand towards high-end models in the Refurbished Equipment segment, which is valued at Rs9945 by 2015 which is estimated the values. Hazards of CT scan CT scanners use intravenously administered contrast agents in order to provide superior image quality. Hence, there is a low, but non-negligible level of risk associated with the contrast agents themselves. Certain patients may experience severe and potentially life-threatening allergic reactions to the contrast dye. The contrast agent may also induce kidney damage. The risk is high in patients who have preexisting renal insufficiency, and diabetes, or reduced intravascular volume. Recent Trends Wider detector coverage State of the art: 64-slice CT has 3.2 to 4.0cm detector width Work-in-progress: 128-slice (expected 2007-2008) and 256-slice CT (expected 2008-2009) for up to 16-cm-wide detector coverage Major Players Blue Star Limited GE Healthcare Siemens Neusoft
Multi-source CT Industry-first: Siemens dual source CT With gantry rotation speed near its maximum, this solution may be the only way to improve temporal resolution Workflow Post-processing software : Computer-aided reading (CAR) and Detection (CAD), Advanced visualization and 3-D/4-D imaging More efficient scanner software Improved clinical applications, in particular cardiac imaging packages Dose reduction Improvements in hardware allow faster procedures, noise reduction
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more successful
Cygnus Business Consulting & Research Pvt. Ltd Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, Behind Image Hospital, Ameerpet, Hyderabad- 500 073. Tel: +91-40-23430203-07, Fax: +91-40-23430201, Email: info@cygnusindia.com; Website: www.cygnusindia.com
Pharma Professional
July 2011
Advanced techniques and algorithms : Automatic exposure control, tube current modulation, ECG pulsing Multi-energy imaging Using a single X-ray source and multi-energy detector: Work in progress, e.g. Philips, GE Tomosynthesis using flat-panel detector (FPD) technology expected to merge with computed tomography (CT) technology in the long-term, pending improvements in FPD technology. Outlook CT scanner market is estimated to grow to Rs7560m by 2012 with CAGR of 18%. Hybrid scanners comprising PET and CT image capabilities are the trend, but a modest growth rate is expected for multi-slice computed tomography scanners. The market is declining for single slice CT scanners where pricing alone seems to determine competition. The US, Europe and Japan account for 85%. Market leaders are GE, Siemens, Toshiba and Philips. The CT scanners market is estimated to increase by 15% in the coming year.
Pharma Professional
July 2011
News News Briefs Briefs
Marketing
Americas USA: Nanoink launches the Nanoarray Assay System Nano BioDiscovery Division announced the launch of a new instrument system for nanoscale protein analysis and discovery. Coupling powerful array deposition techniques with the latest generation of fluorescent detection technologies, the NanoArray Assay System is a user friendly, affordable desktop unit that can quickly and cost-effectively integrate into any proteomic lab. The platform is based on NanoInks patented, tip-based Dip Pen Nanolithography technology, which can create highly reproducible protein arrays over millimeter areas with nanometer precision and then fluorescently image these nanoarrays at high resolution. USA: ImaginAb, announces availability of protein radio labeling services for molecular imaging ImaginAb, Inc. is pleased to announce the availability of custom radio labeling services for proteins, peptides and other macromolecules. This is part of the company's ongoing initiative to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering. Over the past 18 months it has grown its core antibody engineering program to over a dozen 'companion diagnostic' programs with pharmaceutical companies in addition to its own internal pipeline. USA: Biopharma revenues key to Palls Q3 gains Palls biopharmaceutical business contributed revenue of US$197m (136m) for the three months ended April up just over 21% from that recorded in the comparable period in the previous fiscal year. This growth, a part of 16.3% hike to US$368m in total life sciences revenues, maintains the pattern seen in the previous quarter and reflects, according to Pall, the firms role in the expanding vaccine and plasma products markets. Total revenue for the period was also up with the gains in life sciences revenues almost being matched by Palls industrial business, which saw revenue grow 14% to US$341m. USA: Symetic opens process tech demo lab Symetic has opened a new lab facility to showcase its range of processing systems to the pharmaceutical manufacturing, packaging and nutraceutical sectors. The 31,500sqft laboratory, in Wall Washington, US, houses a demonstration area where pharmaceuticals firms can analyse their products and a separate unit where they can conduct factory acceptance testing (FAT) on developmental processes. One of the key features of the new facility is a live video feed that allows those unable to travel to Walla Walla to demonstrations or
Pharma Professional
July 2011
application tests as those present and make observations and ask questions in real-time while their product is being run. USA: RxEvent launched to aid physicians, manufacturers and the US FDA A new online adverse drug event (ADE) network will improve the quality of data and, ultimately, boost drugmakers cost-efficiencies according to developer PDR Network. The RxEvent system is designed to allow physicians to report adverse events via their electronic health records (HER) platforms. This data can then be passed directly to drug makers and the US Food and Drug Administration (FDA). PDR, a distributor of FDA-approved labelling data, alerts and REMS information, developed RxEvent in partnership with Greenway Medical Technologies, American Pharmacists Association and athenahealth. USA: Kareus Therapeutics enters strategic drug development alliance with Quintiles Kareus Therapeutics a company focused on the development of novel therapeutics to address high unmet medical need, announced a broad strategic alliance with Quintiles to progress the development of two of Kareus pre-clinical programs through clinical trials. Under the terms of the alliance, Quintiles will make an investment in Kareus in the US$ seven figure range, apportioned between an equity investment and access to clinical service on a shared-risk basis. Following the investment by Quintiles, Kareus plans to submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity. USA: Lamellar Biomedical Secures its First Orphan Drug Licence Lamellar Biomedical Ltd announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission. The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) earlier this month. The designation of LMS611 as an orphan drug by the European Medicines Agency underscores the importance of developing effective treatments for patients with cystic fibrosis, LMS-611 is developed from Lamellars proprietary inhaled. USA: Pronova BioPharma's PRC-4016 to begin clinical trials for mixed dyslipidemia Pronova BioPharma will announce pre-clinical results of PRC-4016, a new chemical entity for the treatment of mixed dyslipidemia, and the Company is preparing to initiate clinical trials. Mixed dyslipidemia is one of three main types of dyslipidemia, which is caused by an imbalance in the level of blood lipids. Lipids, or fat molecules, include both cholesterol and triglycerides, and dyslipidemia has been shown to play an important role in the development of cardiovascular diseases. Mixed dyslipidemia is characterized by elevated triglycerides (TG) and low high-density lipoprotein-cholesterol (HDL-C) with or without raised LDL cholesterol. USA: CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service CEVEC Pharmaceuticals and Catalent Pharma Solutions announced a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVECs human cell line, CAPTechnology, with Catalents GPEx (Gene Product Expression) Technology to
Pharma Professional
July 2011
generate high expressing stable human cell lines in a much shorter timeframe than traditional methods. Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach. It is a very complex protein produced in our human production cell lines in a very short time frame. USA: Sanofi-aventis enters into Research Collaboration to Develop Potential Treatments for Hearing Loss Audion Therapeutics announced that it has entered into a two-year agreement with Sanofi to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach. This collaborative research will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory. Under the terms of the agreement, Sanofi has an option to license technology rights from Audion related to research conducted under the collaboration. This alliance with Sanofi validates our thinking around developing small molecule regenerative drugs for the treatment of hearing loss. USA: EPA Launches Searchable Database on Chemicals The US Environmental Protection Agency has launched its Web-based chemicals database, ToxRefDB, which allows anyone to search and download thousands of toxicity testing results on hundreds of chemicals. This latest announcement is part of the EPAs policy to increase the transparency of chemical information. In January, the federal agency announced a new policy that gives consumers more access to information on chemicals by rejecting a confidentiality claim by manufacturers on the identity of chemicals. ToxRefDB provides detailed chemical toxicity data available public hazard, exposure, risk assessment data and previous unpublished studies related to cancer, reproductive, and developmental toxicity at your fingertips and in an accessible format. USA: Zimmer launches new range of augments for knee revision surgery Zimmer has launched a new range of Trabecular Metal Material augment shapes and cones to fill small to large cavitary bone defects, provide a structural foundation to the existing bone and help support revision knee implants. The new augments are designed for use with the NexGen Knee System. Trabecular Metal material is a porous biomaterial that resembles the structure, function and physiology of trabecular bone. According to Zimmer, the elasticity of Trabecular Metal Technology provides normal physiological loading which has the potential to decrease stress shielding and improve long-term implant fixation.
Pharma Professional
July 2011
USA: Shimadzu launched highly featured TOC-L Series systems Shimadzu Medical Equipments Private Limited has launched a new series of combustion type analysers. These Total Organic Carbon (TOC)-L Series systems have four models including PC-controlled and separate versions. TOC-L Series systems can be used to supply pharmaceutical water. It considers 680 degree Celsius combustion catalytic oxidation method that can perfectly analyse all organic compounds. It also supports every application to measure organic compounds available in pure or contaminated water because of its measuring range of 4 g/L to 30,000 mg/L. Apart from that, it can also measure liquid, solid and gaseous specimen. USA: NovaBone Products opens new R&D facility in Florida NovaBone Products, which develops bone graft substitutes based on advancements in biomedical engineering that meet the specialized needs of orthopedic and dental surgeons, has opened a new 3,500 square foot dedicated R&D facility in Gainesville, Florida. The new facility provides a platform for NovaBone Products to implement its product development strategy. The company has recently named Gregory Pomrink as VP of R&D. Prior to joining NovaBone Products, Pomrink worked at Orthovita, Dentsply and Integra Life Sciences. USA: Neurotech introduces Kneehab XP Quadriceps therapy system in US Neurotech, a division of Bio-Medical Research (BMR), has introduced Kneehab XP, a surface neurostimulation system to strengthen quadriceps muscles and improve knee stability after surgery in the US. The Kneehab XP system is a conductive garment that features a hand-held controller that delivers stimulation to the quadriceps area of the thigh. The FDA approved Kneehab XP incorporates Multipath, a patented stimulation technology that stimulates the natural muscle recruitment sequence to maximize fiber contractions. Kneehab is indicated for muscle re-education of the quadriceps, increasing range of motion of the knee joint, preventing disuse atrophy in the quadriceps for early post-surgical quadriceps strengthening. USA: Abbott introduces FreeStyle InsuLinx in UK Abbott has introduced FreeStyle InsuLinx Blood Glucose Monitoring System in the UK. The new FreeStyle InsuLinx System comes with a mealtime (bolus) insulin calculator for calculating suggested insulin doses. The bolus calculator feature is designed to help patients administer an accurately calculated suggested dose of insulin to help maintain appropriate blood glucose levels. The new system also offers other features such as a touch screen interface, automated logbook, personalization preferences and USB connectivity for plug-and-play reports via the new FreeStyle Auto-Assist data management software. USA: St Ann's Bay Hospital gets well-needed medical equipment As the fastest-growing union in North America, the Service Employees International Union (SEIU) has extended its reach to Jamaica with assistance to the St Ann's Bay Hospital. The SEIU Local 1 collaborated with Canada's MultiFaith & Community Network and Miracle Centre Ministries to donate more than 42 pieces of medical equipment to the hospital. The items included wheelchairs, resuscitators, walkers, canes and support stands. These were received by senior medical officer of the St Ann's Bay hospital, and the hospital's Chief Executive
Pharma Professional
July 2011
Officer Keith both thanked the SEIU team for the contribution and described the items. USA: Aquino turns over medical equipment to Manila hospital The President Aquino presented the Sta. Ana Hospital with an endoscopy unit after he inaugurated the hospitals newly constructed additional five floors. The President, accompanied by various doctors and Manila Mayor Alfredo Lim, toured and inspected the newly built 6th to 10th floor of the facility, located at Manilas Sta. Ana district. The President stated that the donation of the endoscopy equipment was one way by which the national government was assisting local governments in improving health services.
Pharma Professional
July 2011
USA: Tamale Hospital receives medical equipment Tamale Teaching Hospital has received medical equipment, worth two million US dollars, donated by the Children of Abraham, a group based in Indiana, USA. The equipments include, three cobe dialysis, a machine used for removing waste from the kidney, oxygen tents, ventilators, Western Lloyd neurostat, x-ray view boxes, 11 patient chairs, wheel chairs, medical record rotating table top and bedside monitors. Also, ventilators, suction vacuum pump, physical therapy table, mayo stand, 1,726 boxes of miscellaneous medical supplies, stacker and office chairs and beds, among others. USA: Bluetooth 4.0 will create smarter medical devices The Bluetooth standards body has added support for two specific data types in the Bluetooth 4.0 specification: the Health Thermometer Profile and the Heart Rate Profile. This will give rise to wireless devices that can help monitor and send health information from wearable sensors to smart phones and central monitoring systems, proving Bluetooth still has legs. Expectations for such health devices are high, predicted to be a US$2.1 billion industry by the end of this year and worth US$9.3 billion by 2014. The Health Thermometer Profile and the Heart Rate Profile were built to enable the wireless monitoring of body functions in this case, body temperature and heart rate. While the Bluetooth SIG created the technology, its members, consisting of the leading health, medical and fitness device manufacturers, create the specific ways it will be used. USA: Windows Embedded medical devices Qiagen, a global provider of sample and assay technologies, and InHand Electronics, a provider of low-power embedded systems to OEMs, have joined forces with Microsoft to create a cancer screening device powered by Windows Embedded CE 6.0 R3. The careHPV Test effectively screens women for cervical cancer and HPV even in regions of the world without access to electricity and running water. The availability of the Windows Embedded-powered careHPV Test will help increase early detection of the disease and provide test results to patients within a few hours instead of days. Europe UK: Russian Pharmaceutical Market Driven by Hepatitis C An alarming number of Hepatitis C patients in Russia are driving the country's pharmaceutical industry, with Roche and Schering-Plough benefiting particularly. According to the 'Russian Pharma Sector Forecast to 2013' report compiled by industry intelligence firm RNCOS, augmented use of intravenous drugs and highrisk sexual activities, combined with an unhygienic lifestyle, have caused the disease to steadily increase in Russia. The report indicates that the market would grow at a CAGR of 9% during the 2009-2013 period, with Roche's Pegasys and Schering-Plough's PegIntron medications benefiting from the increase. UK: French Collaboration to Develop Parasite Vaccines Genomic specialist Cellectis and biotech leader VitamFero have signed a research, development and licensing partnership agreement for a new generation of attenuated vaccines. This agreement will grant VitamFero access to Cellectis' proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines. Under the fiveyear agreement, Cellectis will supply VitamFero with pre-selected meganucleases for initial use in the development of vaccines against the parasites responsible for toxoplasmosis and neosporosis, among others. The
Pharma Professional
July 2011
agreement represents an important step, by getting access to Cellectis' intellectual propriety and strengthening its technological potential in the modification of the genomes of apicomplex parasites. India: Pfizer Settles Neurontin Suit Pfizer has settled a dispute with Teva Pharmaceuticals regarding generic versions of epilepsy drug Neurontin, ending a federal court trial. Pfizer had claimed that Teva and its Ivax unit produced copies of the drug that infringed on a patent that does not expire until 2017. As a result, the company sought compensation for lost profit after sales of the drug plunged dramatically from US$2.5 billion to US$150m due to what Pfizer argues as a direct result of lowcost competition. Under the terms of the agreement, Teva will continue to sell the copy under a licence from Pfizer, although financial details have not been disclosed. India: Pfizer Launches First Virtual Trial Pfizer has announced that it is conducting the first-ever 'virtual trial', which will allow patients to participate online from a remote location. The pilot project, initiated following a review from the US Food and Drug Administration (FDA), will use mobile phone and web-based technology to collect necessary data for the trial without clinic visits. The remote trial will access the safety and efficacy of Detrol LA (tolterodine tartrate), a treatment for overactive bladder. Pfizer executive vice-president and chief medical officer say that it is possible for patients to participate in clinical trials without having to visit physical sites. Studies like this could make biomedical science much more accessible to people who have long been excluded from or under-represented in clinical trials. India: Pharmaceutical industry expected to register 12-14% growth in FY12 The domestic pharmaceutical industry is expected to increase by the growth rate of 12 to 14% in the ongoing financial year, as stated by Executive Director, Indian Drug Manufacturers' Association (IDMA). The pharmaceutical sector's total growth on year-on-year basis is to reach around 12 to 14%. By and large, sector's growth in the export market stood by 20 %. In previous financial year, the growth of the global pharmaceutical sector increased to Rs1000 billion and the domestic pharma market has surged to Rs550 billion and the export market also grew to Rs450 billion. The focus areas of Indian pharmaceutical sector, around 5% companies are giving focus in their R&D activities, while some companies are spending more than 10% in their research and development. India: Genome Foundation proposes to create more genome testing labs Genome Foundation is planning to create genome testing laboratories in the remote areas in the country. In this regard, it has submitted a proposal of Rs0.11 billion to the Department of Science and Technology (DST). Genome Foundation is a non-profit organization that has several testing labs like at Kolar in Karnataka and Kalwari in Uttar Pradesh. Now, it is expecting to find approval of the government for its proposal to set up more testing labs in the far-flung areas across the country. The state government of Andhra Pradesh has already allotted 4.3 acres of land in the city for the creation of a well-equipped testing lab. India: Drug companies reduce vaccine rates in developing nations Numerous drug firms have bought down the prices of the vaccine in the developing world. Pharmaceutical companies such as GlaxoSmithKline (GSK),
10
Pharma Professional
July 2011
Merck, Johnson & Johnson and Sanofi-Aventis have decided to bring down the rates via the international vaccine alliance Gavi. GSK has stated that it would be bringing down the price of its vaccine for rotavirus by 67% to US$2.50 per dose in the poor nations. Rotavirus-related diarrhoea kills over 500,000 children every year. The vaccine will then be subsidised by higher rates being charged in the rich nations. India: Vertex Publishes Interim Results of Cystic Fibrosis Combination Therapy Vertex Pharmaceuticals has announced the interim results of combination regimens of VX-770 and VX-809, two drugs to treat cystic fibrosis, from the first part of a Phase II study. The first part of the study enrolled and randomised 62 people with two copies of the mutation in the cystic fibrosis gene, and demonstrated the safety and tolerability of the combination regimen with no serious side effects. The Chief Scientific Officer and Executive Vice-President of global research and development, says that the second part of the study will begin in 2012. The commonly reported adverse events include respiratory symptoms. India: Tata Chemicals Net Rises 8% Tata Chemicals has consolidated net profit for the last fiscal year rose 8% to Rs6.53 billion (US$145.3m) from 6.06 billion rupees the previous year. Consolidated sales for the year through March grew by 15% to Rs108.95 billion from Rs94.48 billion, the maker of fertilizers and inorganic chemicals. Total costs for the last fiscal year increased to Rs96.48 billion from Rs81.51 billion a year earlier. Tata Chemicals its net profit for January-March rose 14% to Rs1.46 billion, while its sales for the quarter climbed 16% to Rs26.58 billion. The Company said its board has recommended a dividend of Rs10 per share. India: MMTC floats tenders for complex fertilizers import Government-owned trading firm MMTC Limited has invited tenders for the import of three grades of complex fertiliser so as to meet the fertiliser demand in the current kharif season. In India, the Kharif season starts with the start of the South-West monsoon from June, while harvesting picks up from October and crops like paddy, pulses and oilseeds are largely grown during this season. The prospective bidders are required to submit furnish details on the quantity of NPK complex fertilisers they want to supply. The shipments should start between July and September and they are to be delivered at the Vizag, Kandla, Rozi and Kakinada ports. India: Blue Star Infotech unveils Oracle Accelerate Solution to capture Indian chemical sector Blue Star Infotech Ltd (BSIL), provider of outcome-based IT solutions, has unveiled an Oracle Accelerate Solution for the Oracle E-Business Suite with the aim to tap the Indian chemical industry. BSIL has all the needed qualifications to implement Oracle Applications using Oracle Business Accelerators for the Indian market. It will be using OBA for Oracle E-Business Suite along with its domain knowledge of the chemical industry. Moreover, the firm will have the capacity to bring down the ERP implementation costs by 25-40% and also the implementation time by 30-40% for the chemical industry. The company is engaged in developing information technology (IT) solutions for enterprises, and building software products for independent software vendors.
11
Pharma Professional
July 2011
India: MMTC invites bids for importing 4,300 tonnes of urea Minerals and Metals Trading Corporation of India (MMTC), a state-run trading company, has invited bids for supplying 4,300 tonnes of urea to numerous industries. The firm has also stated that the net consignment, 3,600 tonnes of urea is to be discharged at the Nava Sheva port near Mumbai, 400 tonnes at the Mundra port in Gujarat, 100 tonnes at the Inland Container Depot (ICD) in Tughlakabad and 200 tonnes at the Chennai port. India: Kerala govt cancels HIL licence to manufacture pesticide endosulfan The State Government has cancelled the licence of Kochi-based Central Government-run Hindustan Insecticides Limited (HIL) to manufacture pesticide endosulfan. The Kerala State Pollution Control Board has issued the closure notice to HIL. However, the company is allowed to manufacture other products but its endosulfan plant will remain closed as the pesticide is blamed for almost 500 deaths in the state since 1995. After the discussions between the Chief Minister, Health Minister and the representatives of the HIL management and the employees union, the company will dispose the pesticide-laden solid waste dumped in the compound in two phases. The phase I is scheduled to be completed within a week and the phase II will be completed in seven months. India: Excel Crop stops production, sale of Endosulfan Excel Crop Care Ltd, a manufacturer of crop protection products has stopped the production and sale of pesticide Endosulfan across the India as the Supreme Court has ordered a countrywide ban on it. As the ad-interim order has been issued during the peak sale season, the performance of the Company in the short term will be adversely affected," according to the statement issued by the company. However, to rationalise the inverse impact on its business, the company is planning to revise its sales plan and marketing strategy. CPIM's youth wing Democratic Youth Federation of India (DYFI) has filed a writ petition before the apex court seeking a ban on sale and production of Endosulfan across the country. India: MMTC want to import di-ammonium phosphate Minerals and Metals Trading Corporation of India (MMTC) has floated bids for the import of di-ammonium phosphate (DAP) just ahead of the commencement of the kharif season in June. The bids will be closing on May 30. The decision on awarding the tender will also be taken on the same day, stated MMTC. The firm has also asked the bidders to quote the quantity of DAP they plan to supply. The shipment period for the consignment is during May-September, 2011. The contracted supplies would have to be delivered at the Kandla, Rozy, Kakinada, Vizag, Tuticorin, New Mangalore and Krishnapatnam ports.
12
Pharma Professional
July 2011
India: Jyothy Labs completes acquisition of 50.97% stake in Henkel India Jyothy Laboratories has completed acquiring 50.97% stake in Henkel India Ltd. (HIL), taking its total shareholding in the Chennai-based firm to 65.88%. The company has acquired 5.94 billion shares aggregating to 50.97 stake in Henkel India, Jyothy Laboratories says in a filing to the Bombay Stock Exchange (BSE). This is subsequent to its announcement last month that it would buy out Germany-based Henkel AG & Cos stake in HIL for Rs1.19 billion. The acquisition, Jyothy Lab has total of 76.70 million shares representing 65.86% stake in Henkel India, the filing added. The company had earlier bought 14.9% stake in HIL from the Indian promoter Tamilnadu Petroproducts for around Rs600m. India: Lanxess selects Singapore for setting up worlds largest Nd-PBR plant Lanxess has selected Singapore as the site for its new neodymium polybutadiene rubber (Nd-PBR) plant. The company plans to invest roughly Euro 200-mn in a 140,000 metric tons per annum facility on Jurong Island Chemical Park. The facility will be the largest of its kind in the world. The plant is expected to start up in the first half of 2015. A corresponding memorandum of Understanding (MoU) was signed between Lanxess CEO and Chairman of the Singapore Economic Development Board (EDB). It is only one year since it has broken ground for its butyl plant in Singapore. Now it is ready to move forward with the second largest investment project in our history.
Mergers & Acquisitions

Americas USA: Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to treat Type-2 diabetes and obesity Zealand Pharma and Boehringer Ingelheim jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity. As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharmas lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first Phase I study with ZP2929. Depending on the achievement of pre-defined development, regulatory and commercial milestones, Zealand Pharma is eligible to receive payments for ZP2929 and may also receive additional milestone payments if other products covered by the collaboration are advanced through development. USA: GEO Specialty Chemicals to acquire UK-based monomer business from BASF GEO Specialty Chemicals Inc has inked a deal with BASF to acquire the Bisomer monomer business (hydroxy methacrylates, multifunctional methacrylates and speciality adducts) and conventional contact lens business of Cognis UK. The transaction includes a manufacturing facility in Hythe, England that produces hydroxy methacrylates, multi-functional methacrylates (MFM) and speciality adducts polyalkylene glycols (PAG) and PAG-based lubricants. This acquisition represents an important strategic addition to GEOs Paints & Coatings business group and it significantly expands its global manufacturing and R&D capabilities, says the Chief Executive Officer of GEO.
13
Pharma Professional
July 2011
USA: Momentive and SSF collaborate on medical devices Momentive Performance Materials Inc. and Specialty Silicone Fabricators plan to collaborate to develop combination products for medical devices manufacturers. The companies announced that the effort will bring together Momentives advanced silicone elastomer technology with SSFs expertise in silicone extrusion and medical device assembly. Silicone is an ideal matrix material to consider for a wide range of healthcare applications, and the firms UV cure technology will enable manufacturers to consider a much broader range of ingredients in their silicone mixtures. SSF plans to expand its API/drug eluting device production into another clean room that will house its own extrusion line and a larger press to meet growing customer demand.
14
Pharma Professional
July 2011
USA: Synthes to be acquired by Johnson and Johnson in US$21 bilion takeover The US healthcare corporation Johnson and Johnson has agreed to buy the Swiss orthopaedic implant manufacturer Synthes in a deal worth US$21.3 billion (13bn). The deal is due to complete in the first half of 2012, subject to shareholder and regulatory approval. Some have speculated that this helps Johnson and Johnson manage the product recalls it has had to deal with in the last year and Synthes has had a reputation as having the highest profit margins in the industry. The acquisition may push Johnson and Johnsons share of the orthopaedic trauma market to around 54%, a market which is expected to grow faster than that for hip and knee replacement, and will also increase their presence in the market for spinal implants. USA: Bacterin signs contract with ROi Bacterin International has agreed to provide the OsteoSponge product line, OsteoSelect DBM Putty, milled and traditional allografts and the Elutia Coated Wound Drain to Resource Optimization and Innovations (ROi) nationwide network of hospitals and medical practices. Bacterin claims its proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth. The products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. USA: D Medical enters into agreement to sell NextGen Biomed D Medical has signed a definitive agreement with a third party for the sale of its holdings in its publicly held subsidiary NextGen Biomed. D Medical will transfer its holdings in NextGen in exchange for NIS 5.5m in cash. D Medical CEO reported that they believe that the additional resources that the completion of this transaction will help them to build upon that momentum. Through its subsidiaries, D Medical is engaged in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D Medical products include durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary springbased delivery technology. USA: HealthTrust enters into spine implant agreement with Pioneer Surgical HealthTrust Purchasing Group has entered into a spine implant agreement with Pioneer Surgical Technology, a provider of orthopedic, spine and biologic systems. HealthTrust is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as 10,600 ambulatory surgery centers, physician practices and alternate care sites. Pioneer Surgical will provide members of HealthTrust access to premium, medical devices for spinal fusion, including cervical and lumbar plates, pedicle screw systems, interbody devices and a minimally-invasive lateral approach system, Cross-Fuse. Some other products are Streamline TL, a thoracolumbar spinal fixation system, and SlimFuse, an anterior cervical plate system. USA: Verisante signs asset purchase agreement with Perceptronix Medical
15
Pharma Professional
July 2011
Verisante Technology, a provider of systems for the early detection of cancer, has entered into an asset purchase agreement with Perceptronix Medical (PMI) under which Verisante has rights to PMI's ClearVu and ClearVu Elite endoscopy systems which are used to detect early lung cancer. The ClearVu system is a simultaneous white light and fluorescence real time video accessory which is used with a fiberoptic bronchoscope for lung cancer examinations. The ClearVu Elite has the addition of reflectance and fluorescence spectral analysis to assess the malignancy potential of suspicious lesions. PMI's technology is complementary to the Verisante Core which uses rapid Raman spectral analysis for the detection of lung cancer. USA: Ortho-McNeil-Janssen Pharmaceuticals Terminates Diabetes Research Agreement Ortho-McNeil-Janssen Pharmaceuticals, a Johnson & Johnson company, has terminated its agreement to develop and commercialise a vaccine for type 1 diabetes. The termination follows last month's evaluation of results of a Phase III study, which showed that the 'Diamyd' vaccine did not reach its primary efficacy endpoint of beta cell function at 15 months in patients newly diagnosed with the disease. The agreement was made in June 2010, when Diamyd Medical received a non-refundable upfront payment of US$45m and the parties began sharing the costs of the programme equally. Following the termination, Diamyd says it has regained control of all rights regarding Diamyd and active substance GAD65. USA: Lilly and Synthes Sign Collaboration Agreement Eli Lilly has signed a worldwide collaboration agreement with medical device manufacturer Synthes to address the needs of patients with bone disorders. The agreement will allow the joint development of early stage compounds to be used by patients in the care of orthopaedic surgeons, including those who suffer from osteoporosis, and the two companies will collaborate to develop osteoinductive medications. Both companies will also conduct and fund work into evaluating Lilly's osteoporosis drug Forteo for other orthopaedic uses, while Forteo will also be copromoted in the US to orthopaedic surgeons under the agreement. Asia-Pacific India: BASF and Ineos sign joint venture contract for Styrolution BASF and Ineos Industries Holdings Ltd. have made an important step towards the establishment of the joint venture company, Styrolution. The companies signed a joint venture contract, which regulates the formation of the joint venture company. BASF and Ineos plan to combine their global business activities in styrene monomers (SM), polystyrene (PS), acrylonitrile butadiene styrene (ABS), styrene-butadiene block copolymers (SBC) and other styrenebased copolymers (SAN, AMSAN, ASA, MABS) as well as copolymer blends into the new joint venture. The company headquarters will be located in Frankfurt/Main, Germany. In the joint venture 50% of the shares will be owned by BASF and 50% by Ineos. India: Iran seeking partner for Hormuz fertiliser plant Iran has announced that it is seeking a new partner to replace Oman in its US$800m Hormuz urea fertiliser plant, according to leading chemical industry information provider, Platts. The project was being carried out in a 50:50 joint venture between Irans National Petrochemical Company and the Oman
16
Pharma Professional
July 2011
Government. However, Oman has showed reluctance to take part in the project after it signed an agreement with National Petrochemical Company.
Investments
Americas USA: APP invests US$38m to boost injectable generics capacity APP Pharmaceuticals will invest US$38m to boost its manufacturing capacity for injectable generic drugs at its facility in Grand Island. The investment will add 13,000 sq of manufacturing space and six new production lines in a project expected to start later this month and take around two years to complete. APP, which employs 580 people at the facility, expects to hire an additional 90 staff. The plant was built in 1970 and has undergone a number of expansions, most recently in 2005 when APP added manufacturing capability for aseptic filling and packaging for pharmaceuticals. APP, which was bought by and makes antiinfectives as well as products for critical care, analgesia, anaesthesia and oncology at the site and claims that growing demand for such drugs, was a key driver for the decision to invest. USA: Tycoon to invest millions in growing biopharma industry Biopharmaceuticals are medical drugs produced using biotechnology. They are produced by means other than direct extraction from a native (non-engineered) biological source. Business News understands that Mellon, whose wealth is worth 550 million, will be investing in the company himself as it undertakes a preflotation fund raising. The money has been investing in United States biopharma companies for the last two years and believes that it is an area set for explosive growth. Biopharma Investments will be investing alongside personal investments in this sector over the coming years. Although any investments carry a certain amount of risk it is acknowledged that research into medicines and pharmacy is something of a boom area.
17
Pharma Professional
July 2011
USA: Vetter Invests in Additional Lyophilization Capacity Vetter has installed three additional state-of-the-art lyophilizers at the companys Ravensburg Vetter South facility, nearly doubling its number of freeze-dryers. Altogether, the site will be able to produce up to 24 million lyophilized units annually. The new equipment increases the number of lyophilizers across all Vetter facilities by 30%. The company made the investment to meet anticipated future demand for aseptically filled biologics and other sensitive compounds, which often require lyophilization to prolong shelf life and potency. In the last three years, more than 30% of all novel drugs approved in the United States were lyophilized, according to the US Food and Drug Administration. Experts predict continued growth. USA: Investment 1.1 million boost for medical devices firm Cork-based Radisens Diagnostics recently secured investment worth up to 1.1 million through Kernel Capital and the Bank of Ireland MedTech Accelerator Fund (500,000), private funding and Enterprise Ireland. The start-up firm has made substantial progress in developing a point of care test which see the future diagnosis of multiple infectious diseases, cancers, cardiac markers and viruses completed within minutes saving lives, reducing patient waiting lists and ensuring optimal use of time in the process. Attracting a high-calibre investor such as Kernel Capital at this early stage in Radisens development significantly endorses our unique value proposition, in what is an US$8 billion market segment. Radisens innovative convergence of medical diagnostics and consumer electronics fields will transform this sector, uniquely addressing clear unmet clinical and commercial needs. USA: Medical device sterilization firm Sterilucent plans new investment US$2m A medical device sterilization business that has focused on serving the military could raise up to US$2m, according to a federal regulatory filing. Sterilucent is developing a quick, efficient and portable sterilization process that caught the eye of the military, which had trouble deploying sterilization equipment to forward bases because of the size of the machinery. The company won a fiveyear contract to deliver its technology to the US Army Combat Casualty Care Hospitals. Sterilucent has operated through a mix of federal contracts, earmarks and grants; some small early stage investments; and revenue from the coatings technology that spawned this business. USA: UK invests in seven personalised medical projects The Medical Research Council and Technology Strategy Board in the UK have announced that they will jointly invest 3.7m in seven major research projects, which will study and develop personalized medicine. The projects will be lead by pharmaceutical companies AstraZeneca UK, GlaxoSmithKline, Ig Innovations, Janssen UK and Randox Laboratories. Four of the projects will develop the use of biomarkers to predict how groups of patients respond to inflammation and immunology therapies. In this way, therapies could be given only to relevant patient subgroups for better results in alleviating symptoms and side effects. The other three projects relate to developing business models to help determine the best ways to co-develop drugs and companion diagnostics. Asia-Pacific India: Evonik invests 150 mn begins production at new monosilane plant in Japan
18
Pharma Professional
July 2011
German chemical group, Evonik Industries, and its partner Taiyo Nippon Sanso Corporation (TNSC) has officially started up the new integrated production facility for monosilane and Aerosil in Yokkaichi, Japan. The project involved investment of around Euro 150-mn and the facility was the companys largest single project in 2010. The process used to produce monosilane at this new plant was developed by Evonik, which already operates a facility using this technology in Rheinfelden (Germany). The new plant in Yokkaichi will serve the Asian market with electronic-grade monosilane. This substantial investment in Japan expands our significant market and technology position in the future-oriented solar energy market. India: Elder Pharma plans Rs1.30 billion investment in research facility Elder Pharma has announced its plans to invest about Rs1.30 billion in its research facility, over the next two-three years. In 2010, the company has upgraded the facility in order to develop new drug delivery systems. In the current year, the company is planning to increase the team in order to develop and market products by the company and its in-licensing partners. Presently, the company has nearly 25 licensing partners, whose products are marketed by Elder Pharma. The company is also considering to start collaborative research work in some of these partnerships. The company is primarily focused on the areas such as prescription products in women's health, nutraceuticals and pain management. The company is all set to market its Rs2 billion Shelcal in Sri Lanka, Bangladesh, and among other markets.
Others
Americas USA: Cancer Protein Discovery May Aid Radiation Therapy Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that paves the way for more-effective radiation treatment of a variety of tumors. Many cancers are driven in part by elevated levels of cyclin D1, which allow the cells to escape growth controls and proliferate abnormally. Nature, researchers discovered that cyclin D1 also helps cancer cells to quickly repair DNA damage caused by radiation treatments, making the tumors resistant to the therapy. Based on this finding, the researchers made cancer cells more sensitive to several cancer drugs and to radiation by using a molecular tool to lower the cancer cells' cyclin D1 levels. USA: Mitsubishi Chemical to enhance PVC production capacity in Thailand Tokyo-headquartered Mitsubishi Chemical Corporation (MCC) will enhance the production capacity of its poly vinylchloride (PVC) facility in Thailand. Work on capacity expansion will begin from April 2012. The capacity will be increased to 15,000 tonnes per annum (tpa) from the existing capacity of 4,000-tpa. The corresponding investment has been planned at approximately Yen 500-mn (about US$6.2m). Asia-Pacific India: WTO demands from Indian govt for offering subsidy on indigenous ammonium sulphate World Trade Organisation (WTO), the primary international body to help strengthen free trade, has asked India to give details for offering subsidy on only indigenous ammonium sulphate and not on the imported fertiliser. Presently, the
19
Pharma Professional
July 2011
Indian government has kept the imported ammonium sulphate out of the boundary of Nutrient-Based Subsidy (NBS) policy. The Fertiliser Ministry is looking at the points that have been raised by WTO and will soon respond to them. India offers subsidy on 22 grades of phosphorous and potassium fertilisers under the NBS Policy on the indigenous and imported fertilisers. The Centre has set the subsidy of Rs5,979-per tonnes for the indigenous produce so that fertiliser is available at affordable price in the Indian market. India: Vicus Therapeutics starts phase II study of VT-122 The biopharmaceutical company Vicus Therapeutics has started a new phase II study of VT-122, by which it hopes to find a breakthrough in liver cancer medication. VT-122 combines two oral generic drugs such as etodolac (a Nonsteroidal anti-inflammatory drug-NSAID) and propranolol. The company is seeking expertise help of pharma-biotech industry and medical institutions for the development and advancement of VT-122. According to the, Director, India Operations of Vicus Therapeutics, all its products can be considered under generic drugs and they are able to improve treatment quality and increase the duration of therapy by lowering the evolution of disease. For the new phase II study of VT-122, the company has already completed pilot study. India: Glenmark wins final nod from US Food and Drug Administration for Mupirocin ointment Glenmark, has bagged final approval from the United States Food and Drug Administration (USFDA) for its generic Mupirocin ointment, which is used for the treatment of bacterial skin infections. Glenmark Generics Inc, an US arm of Glenmark Generics, has won a final abbreviated new drug approval (ANDA) from USFDA for Mupirocin Ointment. According to a statement from Glenmark, Based on IMS health data for the 12-month period ending March 2011, Mupirocin ointment garnered annual sales of US$55m and achieved a 9% increase in growth compared to the same period last year. The ointment is available in a 22gram tube. The firm's present portfolio includes 68 products authorised for distribution in US market. India: ICRA forecasts high good growth rate for research and manufacturing services Investment Information and Credit Rating Agency (ICRA) of India Limited has forecast that the market of Indian Contract Research and Manufacturing Services (CRAMS) would resister a compound annual growth rate (CARG) of 41.4% during the financial year 2011-12.According to ICRA, the total market size would touch the mark of US$7.6 billion with this growth rate. The country is expected to gain good number of United States Food and Drug Administration (US FDA) approvals and more skilled work force during the stipulated period. Furthermore, the inherent cost effectiveness is likely to support the countrys pharma industry for achieving the global pharma outsourcing market of US$67 billion.
FDA Approvals
Americas USA: FDA Approves Drug for Epileptic Seizures The US Food and Drug Administration (FDA) has approved the use of Potiga (ezogabine) tablets to treat seizures associated with epilepsy in adults. Potiga, manufactured by GlaxoSmithKline and Valeant Pharmaceuticals International, is the first neuronal potassium channel opener developed to treat partial seizures,
20
Pharma Professional
July 2011
the most common type of seizure seen in people with epilepsy, a disorder in which there is abnormal or excessive activity of nerve cells in the brain. Although the mechanism of action is not firmly established, the drug may act as an anticonvulsant by reducing excitability through the stabilisation of neuronal potassium channels. Asia-Pacific India: Johnson & Johnson Seeks 11 New Drug Approvals Johnson & Johnson is seeking approval for 11 new drugs by 2015 in an attempt to revive its pharmaceuticals business, including medications for Alzheimer's, diabetes and arthritis. Generic competition to the company's prescription medicines have diminished Johnson & Johnson's earnings over the past two years, and 30 approvals for product line extensions are also being sought. The company expects US regulators to make a decision this year over its blood-clot preventer Xarelto, to be used in patients undergoing hip and knee replacements, whereas its new Type II diabetes treatment canagliflozin could receive US and European approval next year.
Exports & Imports

Asia-Pacific India: Fertilisers and Chemicals Travancore to import urea from Kuwait Fertilisers and Chemicals Travancore (FACT) has announced to import 33,000 tonnes of urea from Kuwait. The consignment of urea is being shipped through 'Star Reliance' and is expected to reach Kochi port by next week. The urea import is targeted to provide necessary fertilisers to farmers before the monsoon and a major portion of the urea would be distributed to the farmers in the state.During the quarter ended March 2011, the company has reported a loss of Rs272.3 billion as against a profit of Rs930 billion in the same quarter last year.
Operations
Asia-Pacific India: AstraZeneca Agrees to Pay US$250,000 to Settle Sex Discrimination Lawsuit AstraZeneca, one of the largest pharmaceutical companies in the world, will pay US$250,000 to 124 women who were subjected to pay discrimination while working at the corporation's Philadelphia Business Center in Wayne, Pa. The action resolves a lawsuit filed by the US Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, US$1,700 less than their male counterparts. The department's Office of Federal Contract Compliance Programs conducted a scheduled compliance review of the business center in 2002.
21
Pharma Professional
July 2011
Product Focus Exelon

Introduction
Exelon (Rivastigmine Tartrate) is a parasympathomimetic or cholinergic agent used for the treatment of mild to moderate dementia of the Alzheimers type and dementia due to Parkinson's disease. It is an AChE inhibitor that works by preventing the breakdown of a chemical called acetylcholine. Other dementia drugs in the market are Pfizers Aricept and Reminyl. The molecular formula of the drug is C14H22N2O2. Working of Exelon Drug Details Drug Brand Exelon (Rivastigmine Name Tartrate ) Active Rivastigmine Ingredient Company Novartis Name Chemical Type Novel Molecular Entity Drug Dose & Capsule with 1.5mg, Type 3mg, 4.5mg and 6mg strength, twice-daily; or Oral Tonic (2mg/mL) or Transdermal Patches Patent Rights Yes Patent Expired Aug 2014 Exelon improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine. People with dementia usually have lower levels of this chemical, which is important for the processes of memory, thinking, and reasoning. Side effects may include nausea and vomiting. Administration with a transdermal patch has fewer side effects compared to oral. Elimination is through the urine. It has likely relatively few drug-drug interactions. Side effects of Exelon People with select biological conditions should take Exelon under doctors supervision. These conditions include heart rhythm disorder such as "sick sinus syndrome" (slow heartbeats), an enlarged prostate, urination problems, asthma, obstructive pulmonary disease, or a seizure disorder such as epilepsy. Exelon is usually taken twice a day, in the morning and evening in the capsule form or in oral solution form. The strength of oral solution form is 2 mg/mL, while that of capsule form are 1.5 mg, 3 mg, 4.5 15 mg and 6 mg. Neurodegenerative disease scenario Neurodegenerative disease (NDD) is a general term for a number of disorders that have different symptoms and effects, all of which
NDD sales In Market
10 Rs bn
22
Cygnus Business Consulting & Research Pvt. Ltd Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, 5 Behind Image Hospital, Ameerpet, Hyderabad- 500 073. Tel: +91-40-23430203-07, Fax: +91-40-23430201, 2011 2013* Email: info@cygnusindia.com; Website: www.cygnusindia.com
Sources: Market Resources; Cygnus Research;*Indicates Estimated results
Pharma Professional
July 2011
act through the mechanism of compromising the brain's capacity to control itself or the body by damaging cells known as neurons that facilitate normal brain function. Alzheimer's disease (AD) is the world's leading cause of dementia and the most prevalent NDD. Around 50-75% of dementia is estimated to be caused by this disease. Parkinson's disease (PD) is the world's second commonest form of NDD. Parkinsonism is a term for a group of disorders that result in symptoms similar to those seen in classic PD NDDs are primarily diseases of older people. With the world's population living longer, the numbers of sufferers are set to rise over the next several decades. NDDs constitute a disease category that the World Health Organization (WHO) calculates will become the world's second leading cause of death by the year 2040, overtaking cancer. Onset of AD most commonly occurs after 65 years of age (only 2% of dementia occurs in patients under 65. Patients are most commonly treated for AD with a class of drugs known as AChE inhibitors, such as Eisai/Pfizer's Aricept (donepezil) and Novartis Exelon. Aricept is the global number-one AD drug, worth US$1.8 billion in 2004. The next largest brand was Novartis' Exelon (rivastigmine), another AChE inhibitor.
Market scenario
Total neurodegenerative disease 700 Demantia Drugs In market (NDD) product sales more than doubled in dollar terms in the period 2010-2011 to reach almost US$6.8 500 billion. The sales are expected to rise to over US$10 billion by 2013. Neurodegenerative diseases (NDD) are destined to become the next 300 great health crusade over the next several decades. This will support sustainable long-term sales growth of NDD products. Growth in the 100 Alzheimer's market will be driven by 2011 2013* the launch of new types of drugs including GABA receptor Sources: Market Resources; Cygnus modulators, anti-amyloid protein Research;*Indicates Estimated Results agents and nicotinic and cholinergic receptor agonists. While growth in the Parkinson's market will be in the medium to long term driven by the launch of glutamate receptor modulators, dopamine receptor agonists and reuptake inhibitors, and andrenergic and adenosine antagonists. The US is the world's single largest NDD products market, worth nearly US$3.3 billion in 2011. Japan and Germany were the next biggest markets. As per the IMS June 2011 Moving Annual Total, the annual sales of Exelon in the US reached US$200m. Exelons worldwide sales in 2013 reached around US$625m.
Indian scenario
Among developing nations, India is the only one where there are as many as six out of the world's 10 biggest pharmaceuticals companies. These companies account for roughly 62% of the total turnover of pharmaceuticals MNCs in India. These MNCs include Glaxo India, Hoechst Marion Roussel, Novartis India, Pfizer, SmithKline Beecham Pharmaceuticals and Wyeth Lederle. MNCs look at India for volume growth and because it is critical to launch new drugs at a reduced time lag. Slower growth in developed markets and heavy generic (off-patent drug)
Rs m
23
Pharma Professional
July 2011
competition has also made the Indian market important. Currently, the market for moderate to severe Alzheimer's dementia is largely untapped in India with Sun Pharma recently launching its own product. The dementia drugs market in India is estimated to have grown from about Rs300m in 2010 to about Rs1600m in 2015.
Outlook
India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. The Indian pharmaceuticals market is expected to reach US$55 billion in 2020 from US$12.6 billion in 2010. Due to increase in the population of high income group, there is every likelihood that they will open a potential US$8 billion market for multinational companies selling costly drugs by 2015. The domestic pharma market is estimated to touch US$20 billion by 2015. The healthcare market in India is to reach US$31.59 billion by 2020. The sale of all types of pharmaceutical drugs and medicines in the country stands at US$ 9.61 billion, which is expected to reach around US$19.22 billion by 2012.
24
Pharma Professional
July 2011
Stock Scan
Relative Market Cap Performance
110
100
90 BSE Sensex 80 18/05/11 23/05/11 25/05/11 26/05/11 31/05/11 01/06/11 02/06/11 06/06/11 07/06/11 08/06/11 09/06/11 10/06/11 14/06/11 14/06/11 15/06/11 15/06/11 16/05/11 17/05/11 19/05/11 20/05/11 24/05/11 27/05/11 30/05/11 03/06/11 13/06/11 13/06/11 Piramal C ipla
Relative Market Cap Performance

110
BSE Sensex SHASUN AUROBINDO
100
90
80 18/05/11 23/05/11 25/05/11 26/05/11 31/05/11 01/06/11 02/06/11 06/06/11 07/06/11 08/06/11 09/06/11 10/06/11 16/05/11 17/05/11 19/05/11 20/05/11 24/05/11 27/05/11 30/05/11 03/06/11
Source: BSE India; Cygnus Research
Index BSE (Points) CIPLA (Rs) PIRAMAL (Rs) SHASUN (Rs) AUROBINDO (Rs)
1st Week (16 -23 May 2nd Week (24th May-30th June 2011) 2011) Openin Closin Var( Opening Closing Var(%) g g %) 18345. 17993. 03 33 -1.92 18011.97 18232.06 1.22 304.20 309.55 1.76 314.55 329.55 4.77 412.95 372.45 -9.81 363.95 371.45 2.06 81.50 84.95 4.23 80.75 76.45 -5.33 194.55 175.55 -9.77 168.70 171.90 1.90
25
Pharma Professional
July 2011
Index BSE (Points) CIPLA (Rs) PIRAMAL (Rs) SHASUN (Rs) AUROBINDO (Rs)
3rd Week (31st May -6th June 2011) Opening 18503.28 326.10 369.45 78.65 176.65 Closing 18420.11 331.60 370.25 75.15 174.20 Var(%) -0.45 1.69 0.22 -4.45 -1.39
4th Week (7-15th June 2011) Openin Closin Var(% g g ) 18495.6 18,132. 2 24 -1.96 337.85 333.00 -1.44 369.00 368.80 -1.44 75.20 78.20 3.99 181.00 177.70 -1.82
26
Pharma Professional
July 2011
Upcoming Events
27
Pharma Professional
July 2011
1.
Event Date Venue Highlight s Contact Details
2.
3.
Event Date Venue
P-Mec Japan Jul 13-15, 2011 Intex Osaka Osaka, Japan It is the abbreviation of Pharmaceutical Machinery & Equipment Convention, which is the exhibition of machine and equipment for pharmaceutical studies development and manufacturing. P-Mec Japan will be held at Intex Osaka. CMP Information Industrieweg 54, P.O. Box 200, 3600 AE, Maarsen, The Netherlands; Tel:+(31)-(346)-559444; Fax: +(31)-(346)-573811 International Modern Hospital Show Jul 13-15, 2011 Tokyo International Exhibition Center (Tokyo Big Sight) Tokyo, Japan It is the only trade show in Japan which is open to the dealers, buyers, doctors, nurses, and medical-related industry people (not open to the public). Over 360 companies participated in IMHS 2010. Nippon Omni-Management Association, 3-11-8 Sendagaya, Shibuya-ku, Tokyo, Japan; Tel:+(81)-(3)-34324720; Fax:+(81)(3)-34324730 WORLDx Congress 2011 Jul 18-20,2011 Hyatt regency Baltimore, 300 Light Street; Baltimore, MD- USA
It is the only event that delivers actionable strategies to help you respond to rapidly evolving regulations, changing reimbursement paradigms, and the alliance management scenarios unique to the diagnostics industry. Here you can build a solid infrastructure of reliable partnerships and commercialization mechanisms, in order to put your research and discovery technology to use in the most practical and profit table manner.
Highlight s
Contact: Matt Greenbaum; Tel: (888) 421-1442, 410.605.2846 E-mail: mgreenbaum@iirusa.com 4. Dye+Chem Jul 20-23, 2011 Bangabandhu International Conference Centre Dhaka, Venue Bangladesh It will be one of the biggest meeting places in Bangladesh for Buyers and Suppliers of Dyes and Chemicals. It will also provide an interactive platform for Exhibitors to generate Highlight business through displays/direct interaction and will enhance s the synergy effect and attract top level professionals from the Industry thus improving technology, focus and visitors of the expo. Conference and Exhibition Management services Limited Contact House # 119, Details Unit- A3, Road-1, Banani Block-F, Dhaka, Bangladesh. Tel: +(880)-(2)-8812713; Fax: +(880)-(2)-9894573 5. Event Clinical Lab Expo Date Jul 26-28, 2011 Georgia World Congress Center Atlanta, United States Of Venue America A joint Initiative by IPA and Cygnus to enable Pharma It is an international scientific/medical exposition of clinical 28 Professionals be more successful Highlight to laboratory professionals, physicians, research scientists and Indian Pharmaceutical Association Cygnus Business Consulting & Research Pvt. Ltd s Kalina, other individuals clinical chemistry and other Santacruz (E), Mumbai 400 098. involved with Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, Tel: 91-22-26671072; Fax: 91-22-26670744, Behind Image Hospital, Ameerpet, Hyderabad500 073. clinical laboratory science-related disciplines. Email:ipacentre@ipapharma.org:: www.ipapharma.org Tel: +91-40-23430203-07, Fax: +91-40-23430201, American Association For Email: Clinical Chemistry1850-K Street, NW info@cygnusindia.com; Website: www.cygnusindia.com Contact Suite 625, Washington, United States Of America; Tel:+(1)Details (800)-8921400
Contact Details Event Date
Pharma Professional
July 2011
29
Pharma Professional
July 2011
6.
Event Date Venue Highlight s Contact Details Event Date Venue Highlight s Contact Details
7.
8.
9.
1 0.
Event Date Venue
Materials for Medical Devices Aug 08-10, 2011 Hilton Minneapolis Minneapolis, United States Of America It is an annual event which brings together over 500 suppliers showcasing their technology, knowledge and capabilities in the medical sciences field. This unique expo witnesses ground breaking technology and innovations in the medical field. It is one of the most highly regarded expo of medical equipments and draws in widespread interest from scientific professionals. ASM9639 Kinsman Road Materials Park, Ohio 44073-0002 USA, Tel:+(1)-(440) 338-5151 Intl. Petroleum & Petrochemical Technology and Equipment Exhibition Aug 11-13, 2011 Canton Fair Pazhou Complex Area B Guangzhou, China It will be the first fine and speciality chemicals exhibition to unite both domestic and international exhibitors. Guangzhou Grandeur Exhibition Service Co. Limited, 2/ F Meijing Garden, No. 318 Chebei Road, Guangzhou, China Tel:+(86)-(20)-28314758; Fax:+(86)-(20)-82579220 CPhi South America Aug 24-26, 2011 Transamerica Expo Center Sao Paulo, Brazil It will undoubtedly bring a wealth of opportunities to the pharmaceutical industry. With a rapidly emerging market second only to China and a growth rate exceeding that of the global average, South America continues to promote an attractive business arena to many Western firms. CMP InformationIndustrieweg 54, P.O. Box 200, 3600 AE, Maarsen, The Netherlands; Tel:+(31)-(346)-559444; Fax: +(31)(346)-573811 Pack Tech Asia Aug 27-29, 2011 Milan Mela Ground Kolkata, India It is an International Exhibition on processing, filling & packaging technology which will showcase the entire spectrum of products, latest Trend, Technology equipments and services in food processing, pharmaceuticals, beverages, confectionery, bakery, Ayurveda and Herbal products, Cosmetics, Agro Products and many more. Kesari Media & Events Pvt. Ltd, Scf 172-A, First Floor, Grain Market Sector-26, Chandigarh, India; Tel:+(91)-(172)-2790007 Pharma eMarketing Congress 2011
13-14 September 2011 Lisbon, Portugal The Pharma eMarketing Congress reflects the dramatic marketing changes in the Pharma industry that were prompted Highlight by technology changes in the past decade. It helps to learn s about Pharmaceutical eMarketing and brainstorm the best A joint Initiative by IPA andbooming Cygnus to enable Pharma 30 practices in this Pharma sector. Professionals PMR,ul. to be more successful Dekerta 24, 30-703, Krakw, Poland; Tel. +48 12 618 90 Contact Indian Pharmaceutical Association Cygnus Business Consulting & Research Pvt. Ltd 00 Kalina, Santacruz (E), Mumbai 400 098. Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, Details Tel: 91-22-26671072; 91-22-26670744, Behind Image Hospital, Ameerpet, Hyderabad- 500 073. Fax Fax: +48 12 618 90 08; E-mail: info@pmrcorporate.com;
Email:ipacentre@ipapharma.org:: www.ipapharma.org Tel: +91-40-23430203-07, Fax: +91-40-23430201, Email: info@cygnusindia.com; Website: www.cygnusindia.com
Pharma Professional
July 2011
31
1 1.
Event
Pharmac India
Date Sep 17-19, 2011 Pharma Professional July 2011 Venue Gujarat University Exhibition Hall It is recognized as a focused exhibition for Pharma & Health care industry. It is 3 days exhibition which is aiming towards Highlight highlighting varied related medical products. It will prove to be a s large hub of reputed professionals from pharmaceutical formulation, herbal products, veterinary drug, medical & disposal, pharmaceutical machinery and many other sectors. Orbitz Exhibitions Private Limited, 202, Navyug Industrial Estate, Contact T. J. Road, Sewree, Mumbai, India; Tel: +(91)-(22)-24102801; Details Fax: +(91)-(22)-24102805 1 Chemical Industry Event 2. Date Sep 26 01, Oct, 2011 Venue International Fair Plovdiv Plovdiv, Bulgaria The first edition of the exhibition was launched in 2004 based on the existing Specialized Salon of Chemical Industry and in Highlight compliance with the modern trends and developments in the s exhibition industry. Our aim is to improve the effectiveness of your participation. International Fair Plovdiv, 37, Tzar Boris III - Obedinitel, Plovdiv, Contact Bulgaria Details Tel:+(359)-(32)-902000; Fax:+(359)-(32)-902432 1 India Chem Gujarat Event 3. Date Oct 13-15, 2011 Venue Gujarat University Exhibition Hall Ahmedabad, Gujarat, India It will showcase potential of the chemical and allied industry. exhibition will offer a platform for discussing varied areas of Highlight The the sector along with the environmental concerns. The event is s being organized by Federation of Indian Chambers of Commerce and Industry. Federation of Indian Chambers of Commerce & Industry, Contact Federation House, 1, Tansen Marg, New Delhi - 110 001, India. Details Tel: +(91)-(11)-23738760; Fax: +(91)-(11)-23320714 1 9th BioPharma India Convention 2011 Event 4. Date Dec 6-8,2011 Venue Mumbai, India It is Indias only event where biopharma industry stakeholders across the entire value chain gather. From partnering to drug Highlight discovery, manufacturing and clinical trial, BioPharma India s Convention brings you the latest developments in India that allow you to be on top of your game. Terrapinn Pte Ltd; 1 Harbourfront Place; #18-01 Harbourfront Contact Tower 1; Singapore 098633; Tel: +65 6222 8550; Fax: +65 Details 6226 3264 website: enquiry.sg@terrapinn.com 1 India Lab Expo Event 5. Date Dec 08-10, 2011 Venue Pragati Maidan New Delhi, Delhi, India It is the India's unique and most comprehensive exhibition on Laboratory, Scientific, Biotechnology, Analytical, Educational, Material Testing, Diagnostics and related products for major Highlight Indian and International manufacturers, exporters, importers and key regional suppliers. This international trade exhibition s A joint Initiative by IPA and Cygnus totechnologies enable Pharma focuses on latest laboratory and accessories. It is32 an ideal platform as a meeting ground for scientists, Professionals to be more successful researchers, and institutional heads and industry captains, to Indian Pharmaceutical Association Cygnus Business Consulting & Research Pvt. Ltd Kalina, Santacruz (E), Mumbai 400 laboratory 098. Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, look at viable solutions. Tel: 91-22-26671072; Fax: 91-22-26670744, Behind Image Hospital, Ameerpet, Hyderabad- 500 073. S. D. India Corporation, No. 595, 2nd Floor, Dr. Mukherjee Email:ipacentre@ipapharma.org:: www.ipapharma.org Tel: +91-40-23430203-07, Fax: +91-40-23430201, Email: info@cygnusindia.com; Website: www.cygnusindia.com Contact Nagar, Details New Delhi - 110 009, India.; Tel: +(91)-(11)-27604500; Fax: +(91)-(11)-27604600
Pharma Professional
July 2011
33

Pharmaceuticals

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Pharmaceuticals

Uploaded by

Copyright:

Available Formats

The The Indian Indian Pharmaceutical Pharmaceutical Association Association

Future growth of ct Scanners

News News Briefs Briefs

Mergers & Acquisitions

Exports & Imports

Product Focus Exelon

Sources: Market Resources; Cygnus Research;*Indicates Estimated results

Relative Market Cap Performance

BSE Sensex SHASUN AUROBINDO

Source: BSE India; Cygnus Research

Event Date Venue Highlight s Contact Details

Event Date Venue Highlight s Contact Details

Event Date Venue

Contact Details Event Date

Event Date Venue Highlight s Contact Details

Event Date Venue Highlight s Contact Details

Event Date Venue

You might also like